Intranasal Epinephrine (ARS-1)
Acute flares of urticaria (hives)
Research/Pre-clinicalActive (Pipeline Advancement)
Key Facts
Indication
Acute flares of urticaria (hives)
Phase
Research/Pre-clinical
Status
Active (Pipeline Advancement)
Company
About ARS Pharmaceuticals
ARS Pharmaceuticals is dedicated to transforming the treatment of severe allergic reactions by developing innovative, needle-free therapies. Its flagship product, neffy, represents a significant advancement in epinephrine delivery, offering a portable, easy-to-use alternative to traditional auto-injectors. The company is now commercializing neffy in the US and advancing its pipeline for other mast-cell mediated conditions. Founded in 2015, ARS Pharma is a public company (NASDAQ: SPRY) with a seasoned leadership team experienced in bringing novel therapies to market.
View full company profile